Back to top

Image: Shutterstock

Novavax's (NVAX) Q1 Loss Widens, Revenues Beat, Shares Down

Read MoreHide Full Article

Novavax, Inc. (NVAX - Free Report) incurred a loss of $3.05 per share in the first quarter of 2021, much wider than the year-ago quarter’s loss of 58 cents, and also falling short of the Zacks Consensus Estimate of a loss of $2.65 per share. This significant loss was due to higher costs to support the development of NVX-CoV2373, its COVID-19 vaccine candidate.

Revenues in the quarter were $447 million, marking a huge improvement from $3 million reported in the year-ago quarter. Revenues increased due to services performed under the agreement with the Coalition for Epidemic Preparedness Innovations and participation in the U.S. government’s Operation Warp Speed in relation to the clinical development of NVX-CoV2373. Revenues beat the Zacks Consensus Estimate of $292 million.

Novavax’s shares were down 12.9% in after-hours trading on Monday. The stock has rallied 43.9% this year so far against the industry’s decrease of 5.2%.

price chart for NVAX


The company announced that it plans to file for authorization in the United States, United Kingdom and the EU in the second quarter of 2021 has been delayed to the third quarter. This was the reason for the stock to do down in after-hours trading despite better-than-expected sales in the quarter.

Quarter in Detail

In the reported quarter, research and development expenses were $593 million, significantly up from $17 million in the year-ago quarter, due to higher expenses for the development of NVX-CoV2373 and higher employee-related costs.

General and administrative expenses also rose significantly year over year to $63 million due to higher employee-related and stock-based compensation expenses, as well as costs for supporting NVX-CoV2373’s development.

Update on COVID-19 Vaccine/Other Pipeline Candidates

NVX-CoV2373 is currently being evaluated in a phase III study. In March 2021, Novavax announced final data from a pivotal phase III study which evaluated NVX-CoV2373 in the United Kingdom. Data from the same showed that the vaccine was 96.4% effective against mild, moderate and severe disease caused by the original coronavirus strain in the United Kingdom.

The company also announced results from the complete analysis of its phase IIb study in South Africa. In the region marked by a vast majority of strains that are B1.351 escape variants, the vaccine candidate delivered 55.4% efficiency among the HIV-negative study participants.

Meanwhile, Novavax is conducting the phase III PREVENT-19 study, which is evaluating the efficacy, safety and immunogenicity of NVX-CoV2373 in the United States and Mexico. The study has enrolled 30,000 participants, with final data from the same expected in the second quarter of 2021. The company has also commenced pediatric expansion of the PREVENT-19 study, to investigate the safety, efficacy and immunogenicity of NVX-CoV2373 in adolescents in the United States.

Please note, Japan-based partner Takeda Pharmaceutical (TAK - Free Report) has enrolled 200 participants in a phase I/II study on NVX-CoV2373 in the Japanese population.

Novavax partnered with the Serum Institute of India to jointly supply 1.1 billion doses of NVX-CoV2373 to Gavi through the COVAX facility. The company will manufacture and distribute 350 million doses to participants of the COVAX facility.

In March 2021, Novavax, reached an agreement in principle Glaxo (GSK - Free Report) and the U.K. government’s vaccines taskforce, to support manufacturing of up to 60 million doses of NVX-CoV2373, for use in the United Kingdom. Glaxo will provide “fill and finish” services for the same.

This apart, Novavax completed a phase III pivotal study on its nanoparticle seasonal influenza vaccine candidate, NanoFlu. The study met all eight primary endpoints. NanoFlu was found non-inferior to Safnofi’s (SNY - Free Report) influenza vaccine, Fluzone.

Novavax will file a biologics license application to the FDA shortly, seeking an accelerated approval for NanoFlu.

Please note that Novavax is also looking to explore a combined NanoFlu/NVX-CoV2373 vaccine, which can be used in a post-pandemic scenario. The company plans to begin clinical study on this combo later in 2021 after pre-clinical data showed that NanoFlu+NVX-CoV2373 induced protective responses against both influenza and SARS-CoV-2.

Novavax, Inc. Price, Consensus and EPS Surprise

Novavax, Inc. Price, Consensus and EPS Surprise


Novavax, Inc. price-consensus-eps-surprise-chart
| Novavax, Inc. Quote

Zacks Rank

Novavax currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Bitcoin, Like the Internet Itself, Could Change Everything

Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.

Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.

See 3 crypto-related stocks now >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Sanofi (SNY) - free report >>

GlaxoSmithKline plc (GSK) - free report >>

Novavax, Inc. (NVAX) - free report >>

Takeda Pharmaceutical Co. (TAK) - free report >>